
CardioTech International, Inc. (AMEX: CTE), a developer and manufacturer of advanced medical devices and materials for the treatment of a broad range of disease states, announced that it has received the necessary Ministry of Health approval to add a 4mm graft for the clinical trial of CardioPass™ , the Company's proprietary synthetic coronary bypass graft.
Click here for full Story http://www.medicalnewstoday.com/articles/106834.php |